PFE - Conference and earnings call announcements

Pfizer Inc. (NYSE:PFE) announced today that its shareholders and the general public are invited to access its virtual 2026 Annual Meeting of Shareholders on Thursday, April 23, 2026, at 9:00 a.m. EDT. Shareholders can find information on accessing and registering for the virtual meeting at https://meetnow.global/PFE2026. On the day of the Annual Meeting, shareholders may begin logging into the virtual meeting platform at 8:45 a.m. EDT using either the control number found on their proxy card, voting instruction form or the notice that was previously received. Only shareholders who log into the meeting using a control number will have the ability to ask questions or vote during the live me

AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of "a+" (Excellent) of Blue Whale Re Ltd. (Blue Whale) (Burlington, VT). The outlook of these Credit Ratings (ratings) is stable. The ratings reflect Blue Whale's balance sheet strength, which AM Best assesses as very strong, as well as its strong operating performance, neutral business profile and appropriate enterprise risk management (ERM). The ratings also reflect Blue Whale's function as the only captive insurer for Pfizer Inc. (Pfizer) (NYSE:PFE), a global pharmaceutical company. As Blue Whale insures or reinsures Pfizer's global property exposures, it plays a strategic and c

Pfizer Inc. (NYSE:PFE) announced today that its shareholders and the general public are invited to access its virtual 2025 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 24, 2025. Pfizer has designed the virtual Annual Meeting to ensure that its shareholders who participate will be afforded comparable rights and opportunities to participate as they would at an in-person meeting. Beginning today, shareholders can find additional information on accessing and registering for the virtual meeting at https://meetnow.global/PFE2025. On the day of the Annual Meeting, shareholders may begin logging into the virtual meeting platform at 8:45 a.m. EDT using either the control numbe

Approved for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV infection in at-risk adults and adolescents aged 12 years and older, weighing at least 35 kg, including men who have sex with men, transgender women, and cisgender women.APRETUDE (cabotegravir extended release injectable suspension) is the first and only long-acting injectable PrEP treatment approved in Canada.Given as few as six times per year after initiation and demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV acquisition in 2 clinical trials.1The latest Canadian surveillance data shows that there were 1,833 new HIV diagnoses in 2022, a 24.9 per

AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of "a+" (Excellent) of Blue Whale Re Ltd. (Blue Whale) (Burlington, VT). The outlook of these Credit Ratings (ratings) is stable. The ratings reflect Blue Whale's balance sheet strength, which AM Best assesses as very strong, as well as its strong operating performance, neutral business profile and appropriate enterprise risk management (ERM). The ratings also reflect Blue Whale's function as the only captive insurer for Pfizer Inc. (Pfizer) (NYSE:PFE), a global pharmaceutical company. As Blue Whale insures or reinsures Pfizer's global property exposures, it plays a strategic and c

More than 50 abstracts, including 11 oral presentations, span Pfizer's robust portfolio of approved and pipeline therapies across its key tumor areas and core scientific modalities New five-year progression-free survival data for LORBRENA® (lorlatinib) in first-line ALK-positive advanced lung cancer Results from ECHELON-3, third Phase 3 study to demonstrate overall survival benefit for ADCETRIS® (brentuximab vedotin) in a type of lymphoma Pfizer Inc. (NYSE:PFE) highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 31 to June 4 in Chicago. More than 50 abstracts, includ

Upon approval, cabotegravir would be the first injectable, long-acting therapy in Canada for HIV prevention.Application is supported by data from the pivotal phase IIb/III studies evaluating safety and efficacy of long-acting cabotegravir for pre-exposure prophylaxis (PrEP) in men who have sex with men, transgender women, and cisgender women at increased risk of HIV acquisition.When given as few as six times per year, cabotegravir for PrEP demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF) tablets in reducing the risk of HIV acquisition.The latest Canadian surveillance data shows that there were 1,833 new HIV diagnoses in 2022, a 24.9 per cent increase from 2021.1MONTRÉAL,

AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of "a+" (Excellent) of Blue Whale Re Ltd. (Blue Whale) (Burlington, VT). The outlook of these Credit Ratings (ratings) is stable. The ratings reflect Blue Whale's balance sheet strength, which AM Best assesses as very strong, as well as its strong operating performance, neutral business profile and appropriate enterprise risk management (ERM). The ratings also reflect Blue Whale's strategic position as the only captive insurer for Pfizer Inc. (Pfizer) (NYSE:PFE), a leading global pharmaceutical company. As Blue Whale insures or reinsures Pfizer's global property exposures, it plays

BASEL, Switzerland and NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV) and Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg). The sNDA proposes updates to MYFEMBREE's United States Prescribing Information (USPI) based on safety and efficacy data from the Phase 3 LIBERTY randomized withdrawal study (RWS) of MYFEMBREE in premenopausal women with heavy menstrual bleeding associated with uterine fibroids for up to two years. The FDA set a target action date of January 29, 2023 for this sN

Final FDA decision anticipated by 24 January 2022; if approved, cabotegravir would be the first long-acting therapy for HIV PrEP ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for a New Drug Application (NDA) for investigational, injectable cabotegravir long-acting for pre-exposure prophylaxis, or PrEP. The Priority Review designation of cabotegravir long-acting for PrEP builds upon its prior identification as a Breakthrough Therapy by the FDA. If approved, cabotegravir would be the first,

Saint-Herblain (France), September 1, 2021 – Valneva SE (NASDAQ:VALN, Euronext Paris: VLA))), a specialty vaccine company, today announced that its senior management will participate in 1-on-1 meetings with institutional investors at the Goldman Sachs Eleventh Annual Biotech Symposium on September 7, 2021.  Valneva's Chief Executive Officer Thomas Lingelbach and acting Chief Financial Officer David Lawrence will notably provide an update on the Company's late stage vaccine candidates against Lyme disease (VLA15), COVID-19 (VLA2001) and chikungunya (VLA1553). Partnered with Pfizer (NYSE:PFE), VLA15 is the only Lyme disease vaccine in clinical development worldwide while VLA2001 is the only

VTX-801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease Paris, France and New York, NY, August 12, 2021 – Vivet Therapeutics ("Vivet"), a clinical-stage biotechnology company, and Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VTX-801, Vivet's clinical-stage gene therapy for the treatment of Wilson Disease – a rare, genetic disorder that reduces the ability of the liver and other tissues to regulate copper levels, causing severe hepatic damage, neurological symptoms, and potentially death. The FDA's Fast Track program is designed to facilitate the development, and expedite the revi

NEW YORK and MAINZ, GERMANY, May 6, 2021— Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) today announced the signing of a Memorandum of Understanding (MoU) with the International Olympic Committee (IOC) to donate the companies' COVID-19 vaccine to help vaccinate athletes, and their delegations, participating in the Olympic and Paralympic Games Tokyo 2020, which are scheduled to begin on July 23, 2021.  Under the MoU, the companies and the IOC will coordinate with National Olympic Committees (NOCs) around the world to understand and work to help address the local need for vaccine doses for national delegations' participation in the Games. Delivery of initial doses to participating

If approved, cabotegravir would be the first, long-acting therapy for HIV PrEP ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc ("GSK"), with Pfizer Inc. and Shionogi Limited as shareholders, today announced the initiation of a rolling submission of a new drug application (NDA) with the US Food and Drug Administration (FDA) for investigational, long-acting, injectable cabotegravir for the prevention of HIV, also called pre-exposure prophylaxis, or PrEP. The rolling submission allows ViiV Healthcare to submit portions of the regulatory application to the FDA as they are completed, rather than waiting until every section of the NDA is complete to subm